spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  lovastatin 

 HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jan 2014
Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 13 Dec 2007
FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR(R) (lovastatin) 20 mg
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Nov 2007
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 29 Oct 2007
Bentley Announces Product Approvals in Spain and Ireland
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 23 Jun 2007
New Study Demonstrates Colesevelam HCl Lowers Both A1C and LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 3 Jul 2006
Abbott's New Tablet Formulation of Kaletra(R) (lopinavir/ritonavir) Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 45

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 45 additional stories matching:
lovastatin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.